Nexletol (Bempedoic Acid): How It Works, Dose, Side Effects

What is Nexletol (bempedoic acid)?

Nexletol is the brand name for bempedoic acid, a once-daily 180 mg pill that lowers LDL cholesterol by reducing how much cholesterol the liver makes. The FDA approved it to lower LDL and to reduce the risk of heart attack and other cardiovascular events in adults who can't take recommended statin therapy (Nexletol prescribing information, DailyMed).

Nexlizet is its sibling, a single tablet that combines bempedoic acid and ezetimibe. Both are made by Esperion.

If you've had muscle aches on statins and someone mentioned "the non-statin pill," they likely meant this one.

How does Nexletol work? (mechanism of action)

Nexletol blocks an enzyme called ATP citrate lyase (ACL) in the liver's cholesterol-making pathway. ACL works upstream of HMG-CoA reductase, the enzyme statins block, so Nexletol cuts cholesterol production one step earlier than a statin does.

Here's the sequence, as the FDA label lays it out (Nexletol prescribing information, section 12.1, DailyMed):

1. You swallow an inactive prodrug. Bempedoic acid does nothing until an enzyme called very long-chain acyl-CoA synthetase 1 (ACSVL1) activates it.
2. The liver switches it on. The label notes that ACSVL1 is expressed primarily in the liver, so that's where the drug becomes active.
3. The active drug blocks ACL. Liver cells make less cholesterol.
4. The liver upregulates LDL receptors. To make up for the shortfall, liver cells put more LDL receptors on their surface, and those receptors pull LDL out of the blood. Your lab report shows that as a lower LDL-C, along with lower non-HDL cholesterol and ApoB.

Why muscle symptoms are less common

Laboratory research found that skeletal muscle lacks ACSVL1, so bempedoic acid stays inactive in muscle. That gives a mechanistic reason the drug may avoid the muscle effects linked to statins.

The CLEAR Outcomes investigators describe bempedoic acid as having a low incidence of muscle-related side effects. Low still means some: in that trial, the label lists muscle spasms in 4% of people on Nexletol and 3% on placebo.

CLEAR Outcomes tested that theory, enrolling only people who couldn't or wouldn't take statins because of side effects.

How effective is Nexletol? (LDL lowering)

Nexletol lowers LDL by roughly 17 to 21% more than placebo, depending on the trial. Combined with ezetimibe as Nexlizet, it lowered LDL by 38% more than placebo.

From the label and the outcomes trial:

• On top of a statin: in the two main LDL trials, the difference from placebo at 12 weeks was 18% and 17%.
• In statin-intolerant people (CLEAR Outcomes): LDL-C started at 139 mg/dL, and after 6 months it was 29.2 mg/dL lower than with placebo, a 21.1 percentage point difference.
• Nexlizet (with ezetimibe): a 38% greater LDL reduction than placebo at 12 weeks (Nexlizet prescribing information, DailyMed).

The label suggests checking lipids 8 to 12 weeks after starting.

What did the CLEAR Outcomes trial show?

CLEAR Outcomes found that bempedoic acid lowered the risk of major cardiovascular events by 13% in people who couldn't tolerate statins. Over a median of 40.6 months, events occurred in 11.7% of people on bempedoic acid and 13.3% on placebo.

The trial enrolled 13,970 people with, or at high risk for, cardiovascular disease who were unable or unwilling to take statins because of side effects. Heart attacks (fatal or nonfatal) dropped from 4.8% to 3.7%, a 23% relative reduction, and artery-opening procedures dropped from 7.6% to 6.2%. There was no significant effect on stroke, cardiovascular death, or death from any cause.

Is Nexletol safe? Side effects

Bempedoic acid can raise uric acid (which can cause gout), and it carries a small increase in gallstones and tendon rupture. Most people in trials kept taking it: in CLEAR Outcomes, 11% stopped because of side effects, compared with 10% on placebo.

The details, from CLEAR Outcomes and the label:

• Uric acid and gout. Bempedoic acid reduces how the kidneys clear uric acid. In the outcomes trial, high uric acid was reported as a side effect in 16.4% of people on the drug and 8.2% on placebo, and gout in 3.1% and 2.1%. Uric acid typically rises within the first 4 weeks and returns to baseline after stopping.
• Gallstones. 2.2% on bempedoic acid and 1.2% on placebo in CLEAR Outcomes.
• Tendon rupture. 1.2% vs 0.9% in the outcomes trial. The label says the risk may be higher over age 60, with corticosteroids or fluoroquinolone antibiotics, with kidney failure, or with a past tendon problem, and advises stopping the drug if a tendon ruptures.
• Lab changes. Small increases in creatinine (a kidney marker) and liver enzymes, and mild anemia, were more common than with placebo.

If you have a history of gout or tendon problems, talk it through before starting. For past tendon problems, the label suggests considering another option; for gout risk, it calls for checking uric acid when indicated and treating it if needed.

What do people taking Nexletol report? (Nexletol reviews)

In trials, most people taking Nexletol reported few problems, and the most common complaints were respiratory infections, muscle spasms, back pain, and high uric acid. This section sticks to what the label and trials recorded, since those numbers come from people who were tracked the same way as the placebo group.

In the label's LDL-lowering trials (2,009 people on Nexletol, 999 on placebo), these reactions showed up most (Nexletol prescribing information, DailyMed):

• Upper respiratory infection: 4.5% on Nexletol and 4.0% on placebo.
• Muscle spasms: 3.6% and 2.3%.
• High uric acid: 3.5% and 1.1%.
• Back pain: 3.3% and 2.2%.
• Abdominal pain or discomfort: 3.1% and 2.2%.

In CLEAR Outcomes (7,001 on Nexletol, 6,964 on placebo), the label lists high uric acid at 16% versus 8%, kidney function changes at 11% versus 9%, muscle spasms at 4% versus 3%, gout at 3% versus 2%, and gallstones at 2% versus 1%. Stopping because of a side effect was about equally common: 11% on Nexletol and 10% on placebo (DailyMed).

Trial groups differ from the people who fill a prescription, and a rate in a trial does not predict your own experience. If something new shows up after you start, tell the prescribing clinician. For gout, tendon pain, or upper-belly pain, do that promptly.

What is Nexlizet, and how does it work? (Nexlizet side effects and uses)

Nexlizet combines bempedoic acid 180 mg and ezetimibe 10 mg in one daily tablet, so it lowers LDL two ways: the liver makes less cholesterol, and the gut absorbs less. In its label trial, Nexlizet lowered LDL by 38% more than placebo at 12 weeks (Nexlizet prescribing information, DailyMed).

The bempedoic acid half works exactly as described above. The ezetimibe half blocks a cholesterol transporter called Niemann-Pick C1-Like 1 (NPC1L1) on the lining of the small intestine. Less cholesterol from the gut reaches the liver, liver cholesterol stores fall, and the liver adds LDL receptors to clear more LDL from the blood. Both halves lead to more LDL receptors, so their effects add up.

What it's approved for. The FDA label approves Nexlizet, alongside diet and exercise, to lower LDL in adults with high cholesterol, including heterozygous familial hypercholesterolemia (an inherited form). Its bempedoic acid component also carries the approval to reduce the risk of heart attack, stroke, cardiovascular death, and artery-opening procedures in adults at increased risk who can't take recommended statin therapy.

Side effects, from the label.

• Common ones in the LDL trials: upper respiratory infections, muscle spasms, high uric acid, back pain, abdominal pain or discomfort, bronchitis, pain in an arm or leg, anemia, raised liver enzymes, diarrhea, joint pain, sinusitis, fatigue, and flu.
• High uric acid and gout (warning). In the LDL trials, 26% of people with normal starting uric acid had a high reading at least once on bempedoic acid, compared with 9.5% on placebo. Uric acid usually rises within the first 4 weeks and returns to baseline after stopping. In CLEAR Outcomes, gout occurred in 3.1% of people on bempedoic acid and 2.1% on placebo.
• Tendon rupture (warning). In the LDL trials, tendon rupture occurred in 0.5% of people on bempedoic acid and none on placebo, involving the rotator cuff, biceps, or Achilles tendon, within weeks to months of starting. The label says to stop the drug right away if a tendon ruptures.
• Gallstones. Gallstones occurred in 2.2% of people on bempedoic acid and 1.2% on placebo in CLEAR Outcomes. The label adds that ezetimibe and fenofibrate can both push more cholesterol into bile, which can lead to gallstones, so it calls for gallbladder tests if gallstones are suspected on that pair and advises against combining Nexlizet with fibrates other than fenofibrate.
• Allergy. Don't take Nexlizet if you've had an allergic reaction to bempedoic acid or ezetimibe.

How do Nexletol, Nexlizet, and ezetimibe compare?

All three are daily non-statin pills, but they work differently and lower LDL by different amounts. Nexletol and ezetimibe each lower LDL by roughly a fifth, and Nexlizet combines them.

Sources: Nexletol and Nexlizet labels (DailyMed), CLEAR Outcomes (Nissen, NEJM 2023), and the Zetia label, where LDL-C fell 18% on ezetimibe and rose 1% on placebo (DailyMed). The numbers come from different trials with different patients, so treat them as ballpark figures. Our ezetimibe guide covers that drug in depth.

What is the Nexletol dosage, and can you take it with a statin?

Nexletol is one 180 mg tablet once a day, with or without food, and many people take it alongside a statin. The label lists a few interactions to know (DailyMed):

• Simvastatin: avoid doses above 20 mg with Nexletol.
• Pravastatin: avoid doses above 40 mg with Nexletol.
• Nexlizet only: because it contains ezetimibe, take it at least 2 hours before or 4 hours after a bile acid binder such as cholestyramine.

The label suggests checking lipids 8 to 12 weeks after starting.

Who is Nexletol a good fit for?

Nexletol fits best for people who can't take a statin, or can only take a low dose, and still need their LDL lower. It also works as an add-on for people on a statin who need a little more.

The 2026 ACC/AHA multisociety cholesterol guideline elevates bempedoic acid to a first-line nonstatin option (ACC). For people with statin intolerance, that puts an option with outcomes data among the first choices.

How far your LDL needs to fall still decides the medicine. If your LDL needs to drop by a fifth to a third, Nexletol or Nexlizet may get you there. If it needs to drop by half or more, a PCSK9 inhibitor such as Repatha, Praluent, the once-monthly Lerochol, or the daily pill Lipfendra lowers LDL far more. Our alternatives to statins guide maps out every option.

How much does Nexletol cost, and is there a copay card?

With commercial insurance, Esperion's co-pay card can bring Nexletol or Nexlizet down to as little as $10 for a 30-day supply or $25 for a 90-day supply, as of October 2026. People with Medicare, Medicaid, or other government coverage aren't eligible for the card (Nexlizet and Nexletol co-pay program).

Esperion states that Nexletol and Nexlizet are covered on most insurance medication plans, though coverage and prior authorization rules vary by plan. We couldn't confirm a current published cash price for Nexletol, so if you plan to pay out of pocket, compare pharmacy discount prices before you fill. If your plan asks for documentation of statin intolerance, that paperwork is easier when your statin history (which ones, what doses, what happened) is written down.

What is the NexStep patient support program for Nexletol and Nexlizet?

NexStep is Esperion's patient support program for Nexletol and Nexlizet. According to the official site, it offers information about why you may need cholesterol treatment and a co-pay card for people with commercial insurance (Nexlizet and Nexletol patient support program, as of October 2026). The page does not list a bridge supply or nurse support.

The co-pay card may lower your cost to as little as $10 for a 30-day supply or $25 for a 90-day supply. To qualify, you must be 18 or older, hold a valid prescription, have commercial drug insurance, live in the US (including DC, but not US territories), and not be enrolled in Medicare, Medicaid, Medigap, TRICARE, or VA coverage. Enrollment runs for one year, so you re-enroll each year. You can enroll at NEXcopay.com or by phone at 855-699-8814 (8 AM to 8 PM Eastern, Monday to Friday, excluding holidays). Esperion decides eligibility, and the card does not promise that your plan covers the drug.

How Preval Health helps

Preval Health focuses only on prescription cholesterol care. A board-certified preventive cardiologist writes our treatment protocols, and licensed clinicians prescribe through our partner telehealth network.

For people who've struggled with statins, our statin intolerance program starts by confirming whether the statin caused your symptoms, then works through options like a lower-dose rechallenge, bempedoic acid, ezetimibe, or a PCSK9 inhibitor, with labs rechecked each quarter. Preval runs as a cash practice, so treatment starts without an insurance approval. If you're further along and need a bigger LDL drop, see how to get a PCSK9 inhibitor prescription online. Care costs $99 a month; medicines cost extra at cash prices.